Daily Cosmetic Research Analysis
Three impactful studies span innovation, surgery, and policy in cosmetic medicine. A skin-on-chip platform enables physiologically relevant nanoparticle safety testing; selective pectoralis muscle denervation reduces capsular contracture after retropectoral breast reconstruction; and a UK-wide survey reveals safety and regulatory gaps in cosmetic botulinum toxin practice.
Summary
Three impactful studies span innovation, surgery, and policy in cosmetic medicine. A skin-on-chip platform enables physiologically relevant nanoparticle safety testing; selective pectoralis muscle denervation reduces capsular contracture after retropectoral breast reconstruction; and a UK-wide survey reveals safety and regulatory gaps in cosmetic botulinum toxin practice.
Research Themes
- Advanced in vitro models for cosmetic ingredient safety
- Surgical innovation to improve reconstructive cosmetic outcomes
- Cosmetovigilance and regulation of aesthetic procedures
Selected Articles
1. A Novel Microfluidic System for 3D Epidermis and Full-Thickness Skin Growth for Nanoparticle Safety Assessment.
The authors developed a modular, perfused skin-on-chip capable of growing epidermis-only and full-thickness human skin equivalents with native-like morphology and barrier. The system maintained metabolic activity and supported nanoparticle exposure studies (e.g., TiO2), addressing key gaps in cosmetic nanoparticle safety testing.
Impact: This platform offers a physiologically relevant alternative to static cultures and animal testing, enabling standardized, reproducible safety evaluation of cosmetic nanoparticles.
Clinical Implications: Improved preclinical safety pipelines for cosmetic ingredients containing nanoparticles, potentially informing regulatory standards and reducing human risk before market entry.
Key Findings
- Developed a dynamic perfusion, modular skin-on-chip supporting both epidermis-only and full-thickness models.
- Models exhibited enhanced barrier function, metabolic activity, and native-like skin morphology compared with static cultures.
- Demonstrated feasibility for nanoparticle toxicity assessment through exposure to titanium dioxide nanoparticles.
Methodological Strengths
- Physiologically relevant dynamic perfusion and modular architecture allowing multiple skin model configurations
- Functional readouts (barrier, metabolic activity, morphology) supporting translational safety testing
Limitations
- In vitro platform without clinical outcome validation
- Limited nanoparticle chemistries and doses reported; inter-laboratory reproducibility not yet established
Future Directions: Expand to diverse nanoparticle chemistries and doses, include immune/appendage components, conduct inter-lab validation, and align protocols with regulatory acceptance.
Chronic skin exposure to nanoparticles (NPs) from air pollution, cosmetics, tattoo inks, and smart textiles is linked to adverse effects such as accelerated aging, dermatitis, eczema, and increased melanoma risk. However, the limited predictive power and physiological relevance of conventional in vitro models, combined with the absence of standardized protocols for assessing NP toxicity, remain a major challenge. To address these limitations, the development of skin-on-chip (SoC) systems provides a more physiologically relevant solution, surpassing the constraints of static skin cultures. Here, a novel SoC model with dynamic perfusion and a modular architecture suitable for epidermis-only (EoC) and full-thickness (FT) skin models isdeveloped. Under dynamic conditions, both models are metabolically active, exhibit enhanced barrier function, and display a morphology resembling native human skin. Exposure to titanium dioxide (TiO
2. Selective Pectoralis Muscle Denervation Reduces Capsular Contracture in Sub-Pectoral Breast Reconstruction. Long-Term Retrospective Case- Control Study.
In a retrospective case-control analysis with a minimum 24-month follow-up, selective denervation of the pectoralis major during retropectoral IBBR significantly reduced capsular contracture rates, confirmed by objective assessments. The average follow-up was 3.33 years, and findings persisted after propensity score adjustment.
Impact: Addresses a common, morbid complication in retropectoral IBBR with a feasible intraoperative modification and objective benefit.
Clinical Implications: For patients unsuitable for prepectoral IBBR, adding selective pectoralis denervation may lower capsular contracture risk and reoperation, improving comfort and cosmetic outcomes.
Key Findings
- Selective pectoralis major denervation during retropectoral IBBR significantly reduced capsular contracture rates.
- Objective outcomes were assessed by three independent clinicians using Baker classification with ≥24 months follow-up.
- Propensity score adjustment confirmed the reduction in capsular contracture in the denervated group.
Methodological Strengths
- Retrospective case-control design with propensity score adjustment
- Objective, blinded-like assessment by multiple independent clinicians and minimum 24-month follow-up
Limitations
- Single-center retrospective design with limited reporting of sample size and selection criteria details
- Potential residual confounding and lack of functional/EMG assessments post-denervation
Future Directions: Prospective multicenter trials to validate efficacy, standardize denervation technique, quantify functional outcomes, and assess long-term reoperation rates.
BACKGROUND: Implant-based breast reconstruction (IBBR) is the most common method of breast reconstruction globally. Although the traditional approach places implants in a retropectoral position, pre-pectoral reconstruction has recently gained popularity due to its improved aesthetic outcomes and lower capsular contracture (CC) rates. However, not all patients are ideal candidates for prepectoral IBBR, making the retropectoral technique still a valuable option. Capsular contracture is a common complication of IBBR, causing discomfort, pain, poor cosmetic results, and often necessitating revision surgery, particularly in retropectoral cases. Selective denervation of the pectoralis major muscle (PMM) in retropectoral IBBR is a novel technique to reduce these complications. MATERIAL AND METHODS: We selected a group of denervated retro-pec IBBR patients and compared them to non-denervated patients. In a previous study, we analyzed the subjective opinions on the reconstruction outcomes using the BREAST-Q postoperative questionnaire. At the same time, we compared retrospectivally the same groups, with a minimum 24-month follow-up, from an objective perspective, evaluating CC rates by Baker scale and possible implant malrotation through outpatient clinic visits performed by three independent breast cancer professionals. RESULTS: The overall mean follow-up was 3.33 (±0.47) years, and the CC rate was significantly lower in Group 1, even adjusting for the propensity score. CONCLUSIONS: PMM selective denervation has gained statistical appreciation by women and significantly reduced the CC rate from an objective evaluation in the setting of retro-pectoral IBBR in our series.
3. Findings From the Great British and Northern Ireland Botulinum Toxin Survey: Treatment Outcomes, Patient Experience, and Regulations From a Cross-Sectional Survey.
A national cross-sectional online survey (n=919) of cosmetic BoNT users in the UK found frequent minor acute complications and low rates of serious long-term issues, but substantial gaps in practitioner qualifications, informed consent, and complication guidance. Most respondents favored stricter regulation.
Impact: Provides real-world cosmetovigilance data at national scale, directly informing patient safety practices and the need for regulatory oversight in cosmetic BoNT.
Clinical Implications: Promotes prescriber-led care, robust consent processes, clear complication guidance, and supports policy actions toward tighter regulation and practitioner accreditation.
Key Findings
- Among 919 respondents, common acute issues were bruising/swelling (26.1%) and headaches (24.7%); long-term problems included BoNT resistance (2.9%) and nerve damage (2.5%).
- 28% reported treatment by a non-prescriber; consent and risk disclosure were incomplete in a notable minority (8% no consent form; 11% not informed of risks).
- Strong public support for tighter regulation: 57.8% favored significantly stricter regulation and 31.3% somewhat stricter regulation.
Methodological Strengths
- Large national sample capturing real-world experiences across settings
- Quantification of both acute and long-term complications alongside consent and regulatory parameters
Limitations
- Self-selected, cross-sectional online survey with potential selection and recall biases
- Self-reported outcomes without medical record verification; practitioner details not independently validated
Future Directions: Establish prospective cosmetovigilance registries with medical verification, evaluate policy impacts of regulatory changes, and define competency standards for providers.
BACKGROUND: Given rising demand for botulinum toxin (BoNT) treatments and limited data on safety, ethics, and regulation, a national survey explored experiences with cosmetic BoNT in the United Kingdom. OBJECTIVES: To conduct a national observational survey with the aim to capture real-world experiences of cosmetic BoNT in the United Kingdom. METHODS: A cross-sectional online survey gathered data on experiences with cosmetic BoNT injections across the United Kingdom. Participation was open to adults (≥18 years) who had received cosmetic BoNT treatment. RESULTS: A total of 919 participants completed the survey and were predominantly female, white, and had a high household income. Commonly reported acute complications were bruising/swelling (26.1%), and headache (24.7%). Commonly reported long-term complications were BoNT resistance (2.9%), social withdrawal (2.7%), nerve damage (2.5%), and dry eyes/vision problems (2.5%). In total, 66% stated their treatment was administered by a prescriber, 28% said it was not. Among those treated by a non-prescriber, 40% reported that a prescriber was present during the consultation, 42% said no prescriber was present, and 17% were unsure. Surprisingly, a few had not signed a consent form (8%), 11% were not informed of treatment risks, and 18% were not told how to respond to complications. A large majority expressed support for enhanced oversight, with 57.8% favoring significantly stricter regulation, and 31.3% somewhat stricter regulation. CONCLUSIONS: Cosmetic BoNT can offer high satisfaction and a favorable safety profile when administered appropriately. However, findings highlight key vulnerabilities: inconsistent practitioner qualifications, gaps in informed consent, insufficient complication support, and weak regulation.